4D Molecular Therapeutics, Inc.
FDMTHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 28
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic. Valued at $468.9M, FDMT is a small-cap name in its sector. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Market Cap
$468.9M
Beta
2.76
P/E (TTM)
—
P/E (Fwd)
-2.41
EPS (TTM)
$-2.57
EPS (Fwd)
$-3.72
ROE
-34.9%
ROA
-21.4%
Cash
$390.9M
Total Debt
$20.5M
Free CF
-$69.4M
52W Change
147.8%
Annual Financials
Cash vs Debt
With $390.9M in cash and $20.5M in debt, FDMT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$69.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -34.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $3.1M (2022) to $85.2M (2025), reflecting a 2623% increase over the period.
With a beta above 1.5, FDMT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, FDMT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FDMT.